Evidence map›Paper›PMID 15339859›Full record

ArticleBritish journal of pharmacology2004

Mechanisms intrinsic to 5-HT2B receptor-induced potentiation of NMDA receptor responses in frog motoneurones.

Alice M Holohean, John C Hackman

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Positive regulation of raphe serotonin neurons by serotonin 2B receptors.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018
    Article
  4. Presynaptic serotonin 5-HTJournal of comparative physiology. A, Neuroethology, sensory, neural, and behavioral physiology · 2018
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Alice M HoloheanSpinal Cord Pharmacology Laboratory, Veterans Affairs Medical Center, Miami, FL 33101, USA.
John C Hackman
University of Miami · USVeterans Health Administration · US

Funding

Synapses,Channels, and Transduction in NeuroscienceT32NS007044 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI MULLER, KENNETH J · 1985 to 2010
$2.2M
MULTIPLE SEROTONIN RECEPTORS ON THE SAME CELLR01NS030600 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HACKMAN, JOHN C. · 1993 to 1996
–
NINDS NIH HHS 5T32NS07044NINDS NIH HHS NS 30600NINDS NIH HHS T32 NS007044
6 · The paper itself

Abstract

In the presence of NMDA receptor open-channel blockers [Mg(2+); (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801); 1-amino-3,5-dimethyladamantane (memantine)] and TTX, high concentrations (30-100 microm) of either 5-hydroxytryptamine (5-HT) or alpha-methyl-5-hydroxytryptamine (alpha-Me-5-HT) significantly potentiated NMDA-induced depolarizations of frog spinal cord motoneurones. Potentiation was blocked by LY-53,857 (10-30 microm), SB 206553 (10 microm), and SB 204741 (30 microm), but not by spiroxatrine (10 microm), WAY 100,635 (1-30 microm), ketanserin (10 microm), RS 102221 (10 microm), or RS 39604 (10-20 microm). Therefore, alpha-Me-5-HT's facilitatory effects appear to involve 5-HT(2B) receptors. These effects were G-protein dependent as they were prevented by prior treatment with guanylyl-5'-imidodiphosphate (GMP-PNP, 100 microm) and H-Arg-Pro-Lys-Pro-Gln-Gln-D-Trp-Phe-D-Trp-D-Trp-Met-NH(2) (GP antagonist 2A, 3-6 microm), but not by pertussis toxin (PTX, 3-6 ng ml(-1), 48 h preincubation). This potentiation was not reduced by protein kinase C inhibition with staurosporine (2.0 microm), U73122 (10 microm) or N-(2-aminoethyl)-5-isoquinolinesulfonamide HCl (H9) (77 microm) or by intracellular Ca(2+) depletion with thapsigargin (0.1 microm) (which inhibits Ca(2+)/ATPase). Exposure of the spinal cord to the L-type Ca(2+) channel blockers nifedipine (10 microm), KN-62 (5 microm) or gallopamil (100 microm) eliminated alpha-Me-5-HT's effects. The calmodulin antagonist N-(6-aminohexyl)-5-chloro-1-naphtalenesulfonamide (W7) (100 microm) diminished the potentiation. However, the calcium/calmodulin-dependent protein kinase II (CaM Kinase II) blocker KN-93 (10 microm) did not block the 5-HT enhancement of the NMDA responses. In summary, activation of 5-HT(2B) receptors by alpha-Me-5-HT facilitates NMDA-depolarizations of frog motoneurones via a G-protein, a rise in [Ca(2+)](i) from the entry of extracellular Ca(2+) through L-type Ca(2+) channels, the binding of Ca(2+) to calmodulin and a lessening of the Mg(2+) -produced open-channel block of the NMDA receptor.

Indexed as

1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineAnimalsCalciumCalcium-Calmodulin-Dependent Protein KinasesCalcium Channel BlockersDizocilpine MaleateDose-Response Relationship, DrugDrug SynergismEnzyme InhibitorsErgolinesExcitatory Amino Acid AntagonistsGallopamilGTP-Binding ProteinsGuanylyl ImidodiphosphateIndolesMagnesium1-(5-Isoquinolinesulfonyl)-2-Methylpiperazinealpha-methylserotoninCalciumCalcium-Calmodulin-Dependent Protein KinasesCalcium Channel BlockersDizocilpine MaleateEnzyme InhibitorsErgolinesExcitatory Amino Acid AntagonistsGallopamilGTP-Binding ProteinsGuanylyl ImidodiphosphateIndolesKN 62LY 53857MagnesiumMemantineNifedipineN-MethylaspartateProtein Kinase CPyridinesReceptor, Serotonin, 5-HT2BReceptors, N-Methyl-D-AspartateSB 206553SerotoninSerotonin 5-HT2 Receptor AgonistsSerotonin 5-HT2 Receptor AntagonistsSerotonin AntagonistsSerotonin Receptor AgonistsStaurosporineSulfonamidesTetrodotoxinW 7

Identifiers

PMID15339859
PMCPMC1575347
OpenAlexW2092281304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.